(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 0 504 363 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
21.01.1998 Bulletin 1998/04

(21) Application number: **91917891.3**

(22) Date of filing: **17.10.1991**

(51) Int Cl.[6]: **C12P 21/08**, C07K 16/06, C07K 16/28, A61K 39/395

(86) International application number:
PCT/GB91/01816

(87) International publication number:
WO 92/07084 (30.04.1992 Gazette 1992/10)

(54) **PURIFIED IgG ANTIBODIES**

GEREINIGTE IgG ANTIKÖRPER

ANTICORPS IgG PURIFIES

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: **17.10.1990 GB 9022547**

(43) Date of publication of application:
23.09.1992 Bulletin 1992/39

(73) Proprietor: **THE WELLCOME FOUNDATION LIMITED**
Greenford, Middlesex UB6 0NN (GB)

(72) Inventors:
- **RAMAGE, Paul, Ian, Nicholas**
  CH-4153 Reinach (CH)
- **ALLEN, Geoffrey Langley Court**
  Kent BR3 3BS (GB)

(74) Representative: **Stott, Michael John et al**
Glaxo Wellcome plc,
Glaxo Wellcome House,
Berkeley Avenue
Greenford, Middlesex UB6 0NN (GB)

(56) References cited:
WO-A-89/05157

- **THE LANCET, 17 December 1988, London, GB., G. HALE et al., "Remission Induction in Non-Hodgkin Lymphoma With Reshaped Human Monoclonal Antibody CAMPATH-1H", pages 1394-1399.**
- **BIOPHARM, Vol. 2, No. 6, June 1989, Eugene, Oregon, USA., S. DUFFY et al., "Recovery of Therapeutic-grade Antibodies: Protein A and Ion-exchange Chromatography", pages 34-45.**
- **JOURNAL OF BIOTECHNOLOGY, Vol. 9, No. 2, January 1989, Amsterdam, NL., J. KENNEDY et al., "The Use of HPLC in Biotechnology. Minireview", pages 83-106.**

EP 0 504 363 B1

Printed by Jouve, 75001 PARIS (FR)

First Hit

End of Result Set

Generate Collection | Print

L2: Entry 1 of 1 File: DWPI Jul 29, 2003

DERWENT-ACC-NO: 1992-167163
DERWENT-WEEK: 200356

TITLE: Immunosuppressant purified anti-CDW52 antibody preparations - for treating e.g. T-cell mediated diseases, rheumatoid arthritis, multiple sclerosis, diabetes, asthma, cancer, etc.

INVENTOR: ALLEN, G; RAMAGE, P I N ; RAMAGE, P I ; RAMAGE, P I M ; RAMAGAGE, P I N

PATENT-ASSIGNEE: WELLCOME FOUND LTD (WELL), BURROUGHS WELLCOME CO (WELL)

PRIORITY-DATA: 1990GB-0022547 (October 17, 1990)

Search Selected | Search ALL | Clear

PATENT-FAMILY:

	PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
☐	CA 2069481 C	July 29, 2003	E	000	C12N015/13
☐	WO 9207084 A1	April 30, 1992	E	043	C12P021/08
☐	FR 2668164 A1	April 24, 1992		044	
☐	AU 9187294 A	May 20, 1992		000	
☐	FI 9202380 A	May 25, 1992		000	A61K
☐	GB 2253397 A	September 9, 1992		048	C07K003/28
☐	EP 504363 A1	September 23, 1992	E	043	
☐	FI 9202824 A	June 17, 1992		000	A61K000/00
☐	BE 1004226 A5	October 13, 1992		048	C12P000/00
☐	FR 2677997 A1	December 24, 1992		043	
☐	AU 9225321 A	February 11, 1993		000	C07K003/28
☐	CH 681305 A5	February 26, 1993		000	C07K015/28
☐	CH 681455 A5	March 31, 1993		000	C07K015/28
☐	LU 88122 A	March 15, 1993		000	C12P012/08
☐	PT 99248 A	June 30, 1993		000	C07K000/00
☐	ZA 9108259 A	June 30, 1993		041	C12P000/00
☐	ZA 9206191 A	June 30, 1993		042	C12P000/00
☐	JP 05504579 W	July 15, 1993		014	C07K015/14
☐	HU 64601 T	January 28, 1994		000	
☐	PT 100988 A	February 28, 1994		000	A61K039/44
☐	AU 649078 B	May 12, 1994		000	C07K003/28
☐	NZ 240247 A	March 25, 1994		000	C07K015/06
☐	AU 9470242 A	January 5, 1995		000	C07K015/12
	AU 658926 B	May 4, 1995		000	C07K003/28

NZ 244114 A	June 27, 1995		000	A61K039/395
IT 1250064 B	March 30, 1995		000	A61K000/00
ES 2081742 A1	March 1, 1996		000	C12P021/08
AT 9109007 A	June 15, 1996		000	C12P021/08
ES 2081742 B1	October 1, 1996		000	C12P021/08
TW 283710 A	August 21, 1996		000	C07K015/28
US 5644036 A	July 1, 1997		015	C07K001/18
JP 2638680 B2	August 6, 1997		016	A61K039/395
EP 504363 B1	January 21, 1998	E	023	C12P021/08
AU 9745218 A	February 12, 1998		000	C07K016/24
DE 69128774 E	February 26, 1998		000	C12P021/08
BR 1100358 A3	April 14, 1998		000	C07K001/34
ES 2112865 T3	April 16, 1998		000	C12P021/08
KR 9615399 B1	November 13, 1996		000	A61K039/395
AU 716402 B	February 24, 2000		000	C07K016/24
KR 193314 B1	June 15, 1999		000	A61K039/395
MX 195018 B	January 20, 2000		000	C12P021/008
IL 102726 A	August 14, 2002		000	C12P021/08
FI 110002 B1	November 15, 2002		000	C07K001/16
FI 110003 B1	November 15, 2002		000	C07K001/16

DESIGNATED-STATES: AT AU CA CH ES FI GB HU JP KR LU US AT BE CH DE DK ES FR GB GR IT LU NL SE AT BE CH DE DK ES FR GB GR IT LI LU NL SE AT BE CH DE DK ES FR GB GR IT LI LU NL SE

CITED-DOCUMENTS:No-SR.Pub; 3.Jnl.Ref ; WO 8905157

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
CA 2069481C	October 17, 1991	1991CA-2069481	
CA 2069481C	October 17, 1991	1991WO-GB01816	
CA 2069481C		WO 9207084	Based on
WO 9207084A1	October 17, 1991	1991WO-GB01816	
FR 2668164A1	October 16, 1991	1991FR-0012738	
AU 9187294A	October 17, 1991	1991AU-0087294	
AU 9187294A	October 17, 1991	1991WO-GB01816	
AU 9187294A		WO 9207084	Based on
FI 9202380A	October 17, 1991	1991WO-GB01816	
FI 9202380A	May 25, 1992	1992FI-0002380	
GB 2253397A	October 17, 1991	1991WO-GB01816	
GB 2253397A	May 1, 1992	1992GB-0009529	
GB 2253397A		WO 9207084	Based on
EP 504363A1	October 17, 1991	1991EP-0917891	
EP 504363A1	October 17, 1991	1991WO-GB01816	
EP 504363A1		WO 9207084	Based on
FI 9202824A	October 17, 1991	1991WO-GB01816	
FI 9202824A	October 17, 1991	1992FI-0002380	Div ex

FI 9202824A	June 17, 1992	1992FI-0002824	
BE 1004226A5	October 16, 1991	1991BE-0000946	
FR 2677997A1	August 13, 1992	1992FR-0009998	
AU 9225321A	September 23, 1992	1992AU-0025321	
AU 9225321A		1991AU-0087294	Div ex
CH 681305A5	October 17, 1991	1991WO-GB01816	
CH 681305A5	October 17, 1991	1992CH-0001901	
CH 681305A5		WO 9207084	Based on
CH 681455A5	October 17, 1991	1992CH-0001901	Div ex
CH 681455A5	October 17, 1991	1992CH-0002655	
LU 88122A	October 17, 1991	1991WO-GB01816	
LU 88122A	May 27, 1992	1992LU-0088122	
LU 88122A		WO 9207084	Based on
PT 99248A	October 16, 1991	1991PT-0099248	
ZA 9108259A	October 16, 1991	1991ZA-0008259	
ZA 9206191A	August 17, 1992	1992ZA-0006191	
JP 05504579W	October 17, 1991	1991JP-0516509	
JP 05504579W	October 17, 1991	1991WO-GB01816	
JP 05504579W		WO 9207084	Based on
HU 64601T	October 17, 1991	1991WO-GB01816	
HU 64601T	October 17, 1991	1992HU-0002000	
HU 64601T		WO 9207084	Based on
PT 100988A	October 20, 1992	1992PT-0100988	
AU 649078B	October 17, 1991	1991AU-0087294	
AU 649078B		AU 9187294	Previous Publ.
AU 649078B		WO 9207084	Based on
NZ 240247A	October 16, 1991	1991NZ-0240247	
AU 9470242A	October 17, 1991	1991AU-0087294	Div ex
AU 9470242A	August 11, 1994	1994AU-0070242	
AU 658926B	October 17, 1991	1991AU-0087294	Add to
AU 658926B	September 23, 1992	1992AU-0025321	
AU 658926B		AU 9225321	Previous Publ.
NZ 244114A	October 16, 1991	1991NZ-0244114	
NZ 244114A		NZ 240247	Div ex
IT 1250064B	October 16, 1991	1991IT-RM00788	
ES 2081742A1	October 17, 1991	1992ES-0050029	
AT 9109007A	October 17, 1991	1991AT-0009007	
AT 9109007A	October 17, 1991	1991WO-GB01816	
ES 2081742B1	October 17, 1991	1992ES-0050029	
TW 283710A	October 16, 1991	1991TW-0108178	
US 5644036A	October 16, 1991	1991US-0777731	Cont of
US 5644036A	November 13, 1992	1992US-0975967	Cont of
US 5644036A	December 3, 1992	1992US-0985272	Cont of
US 5644036A	September 12, 1994	1994US-0304440	Cont of
US 5644036A	October 7, 1994	1994US-0319598	
JP 2638680B2	October 17, 1991	1991JP-0516509	
JP 2638680B2	October 17, 1991	1991WO-GB01816	
JP 2638680B2		JP 5504579	Previous Publ.
JP 2638680B2		WO 9207084	Based on
EP 504363B1	October 17, 1991	1991EP-0917891	
EP 504363B1	October 17, 1991	1991WO-GB01816	
EP 504363B1		WO 9207084	Based on

AU 9745218A	October 17, 1991	1991AU-0087294	Div ex
AU 9745218A	November 13, 1997	1997AU-0045218	
DE 69128774E	October 17, 1991	1991DE-0628774	
DE 69128774E	October 17, 1991	1991EP-0917891	
DE 69128774E	October 17, 1991	1991WO-GB01816	
DE 69128774E		EP 504363	Based on
DE 69128774E		WO 9207084	Based on
BR 1100358A3	April 28, 1997	1997BR-1100358	
ES 2112865T3	October 17, 1991	1991EP-0917891	
ES 2112865T3		EP 504363	Based on
KR 9615399B1	October 17, 1991	1991WO-GB01816	
KR 9615399B1	June 16, 1992	1992KR-0701427	
AU 716402B	October 17, 1991	1991AU-0087294	Div ex
AU 716402B	November 13, 1997	1997AU-0045218	
AU 716402B		AU 649078	Div ex
AU 716402B		AU 9745218	Previous Publ.
KR 193314B1	October 17, 1991	1991WO-GB01816	
KR 193314B1	June 16, 1992	1992KR-0701427	Div ex
KR 193314B1	October 30, 1992	1992KR-0702699	
MX 195018B	June 29, 1992	1992MX-0003794	
IL 102726A	October 16, 1991	1991IL-0099761	Div ex
IL 102726A	October 16, 1991	1991IL-0102726	
IL 102726A		IL 99761	Div ex
FI 110002B1	October 17, 1991	1991WO-GB01816	
FI 110002B1	May 25, 1992	1992FI-0002380	Div ex
FI 110002B1	June 17, 1992	1992FI-0002824	
FI 110002B1		FI 9202824	Previous Publ.
FI 110003B1	October 17, 1991	1991WO-GB01816	
FI 110003B1	May 25, 1992	1992FI-0002380	
FI 110003B1		FI 9202380	Previous Publ.

9206191 A INT-CL (IPC): A61K 0/00; A61K 39/395; A61K 39/44; A61K 255/31; C07K 0/00; C07K 1/16; C07K 1/18; C07K 1/22; C07K 1/34; C07K 1/36; C07K 3/18; C07K 3/20; C07K 3/22; C07K 3/28; C07K 15/06; C07K 15/12; C07K 15/14; C07K 15/28; C07K 16/06; C07K 16/24; C07K 16/28; C07K 16/42; C07K 271/26; C12N 15/13; C12P 0/00; C12P 12/08; C12P 21/008; C12P 21/08

ABSTRACTED-PUB-NO: EP 504363B
BASIC-ABSTRACT:

Following are described. (A) purified prepn. of an anti-CDw52 antibody which exhibits on size exclusion chromatography a single peak under non-reducing conditions and 2 major peaks under reducing conditions; esp. the prepn. exhibits on conventional SDS polyacrylamide gel electrophoresis, one main band using a non-reduced sample and two main bands using a reduced sample; (B) purified prepn. of an anti-CDw52 antibody having a specific activity greater than 0.8 KU/mg; (C) purified prepn. of an anti-CDw52 antibody, free from host cell contaminants and/or aggregates; (D) purifying an anti-CDw52 antibody comprising (a) applying an aqs. soln. of the antibody to a Protein A column so as to absorb the antibody and eluting the antibody with an acid soln., (b) applying the acidic eluate to an ion-exchange column of charged particles to absorb the antibody and then eluting the antibody with an aqs. soln. of counter-charged ions and (c) applying the aqs. eluate to a size exclusion column of porous particles to retain non-antibody mols. in the porous particles and to obtain the desired antibody in selected fractions produced from the column.

Pref. the Protein A column is Protein A Sepharose and the antibody is eluted with citric acid.

USE - Purified anti-CDw52 antibodies are useful as immunosuppressives for treating T-cell mediated disorders including severe vasculitis, rheumatoid arthritis, systemic lupus, and also

autoimmune disorders such as multiple sclerosis, graft vs. host disease, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, myasthenia gravis, transplant rejection and asthma. Antibodies are also useful in treating cancers e.g. Non-Hodgkins lymphoma and leukemias.

ABSTRACTED-PUB-NO: US 5644036A
EQUIVALENT-ABSTRACTS:

Following are described. (A) purified prepn. of an anti-CDw52 antibody which exhibits on size exclusion chromatography a single peak under non-reducing conditions and 2 major peaks under reducing conditions; esp. the prepn. exhibits on conventional SDS polyacrylamide gel electrophoresis, one main band using a non-reduced sample and two main bands using a reduced sample; (B) purified prepn. of an anti-CDw52 antibody having a specific activity greater than 0.8 KU/mg; (C) purified prepn. of an anti-CDw52 antibody, free from host cell contaminants and/or aggregates; (D) purifying an anti-CDw52 antibody comprising (a) applying an aqs. soln. of the antibody to a Protein A column so as to absorb the antibody and eluting the antibody with an acid soln., (b) applying the acidic eluate to an ion-exchange column of charged particles to absorb the antibody and then eluting the antibody with an aqs. soln. of counter-charged ions and (c) applying the aqs. eluate to a size exclusion column of porous particles to retain non-antibody mols. in the porous particles and to obtain the desired antibody in selected fractions produced from the column.

Pref. the Protein A column is Protein A Sepharose and the antibody is eluted with citric acid.

USE - Purified anti-CDw52 antibodies are useful as immunosuppressives for treating T-cell mediated disorders including severe vasculitis, rheumatoid arthritis, systemic lupus, and also autoimmune disorders such as multiple sclerosis, graft vs. host disease, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, myasthenia gravis, transplant rejection and asthma. Antibodies are also useful in treating cancers e.g. Non-Hodgkins lymphoma and leukemias.

Process for obtaining a purified IgG antibody preparation which comprises:

(a) culturing a recombinant mammalian cell line capable of producing the antibody in an aqueous culture medium under antibody producing conditions;

(b) applying the antibody-containing aqueous medium to a Protein A column or Protein G column so as to absorb the antibody onto the column and then eluting the antibody with an acidic solution to produce an acidic eluate;

(c) applying the acidic eluate to an ion exchange column of charged particles previously equilibrated with a neutral buffer so as to absorb the antibody and then eluting the antibody with a neutral aqueous solution of counter-charged ions; and

(d) applying the aqueous eluate to a size exclusion column of porous particles so as to separate aggregates and other non-antibody molecules from the desired antibody and to obtain the desired antibody in selected fractions eluted from the column.

WO 9207084A

CHOSEN-DRAWING: Dwg.0/6 Dwg.0/6 Dwg.0/0

DERWENT-CLASS: B04 D16
CPI-CODES: B04-B04C; B12-A07; B12-C10; B12-D02; B12-D03; B12-D07; B12-E01; B12-E02; B12-G05; B12-G06; B12-G07; B12-K02; D05-H11;

ANSWER 3 OF 3 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1992-167163 [20] WPIDS

DNC C1992-076899

TI Immunosuppressant purified anti-**CDW52** antibody preparations - for treating e.g. T-cell mediated diseases, rheumatoid arthritis, **multiple sclerosis**, diabetes, asthma, cancer, etc..

DC B04 D16

IN ALLEN, G; RAMAGE, P I N; RAMAGE, P I; RAMAGE, P I M; RAMAGAGE, P I N

PA (WELL) WELLCOME FOUND LTD; (WELL) BURROUGHS WELLCOME CO

CYC 28

PI

WO 9207084	A1	19920430	(199220)*	EN	43p
RW: AT BE CH DE DK ES FR GB GR IT LU NL SE					
W: AT AU CA CH ES FI GB HU JP KR LU US					
FR 2668164	A1	19920424	(199224)		44p
AU 9187294	A	19920520	(199233)		
FI 9202380	A	19920525	(199235)		
GB 2253397	A	19920909	(199237)		48p
EP 504363	A1	19920923	(199239)	EN	43p
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
FI 9202824	A	19920617	(199239)		
BE 1004226	A5	19921013	(199250)		48p
FR 2677997	A1	19921224	(199308)		43p
AU 9225321	A	19930211	(199313)		
CH 681305	A5	19930226	(199314)		
CH 681455	A5	19930331	(199318)		
LU 88122	A	19930315	(199318)		
PT 99248	A	19930630	(199329)		
ZA 9108259	A	19930630	(199331)		41p
ZA 9206191	A	19930630	(199331)		42p
JP 05504579	W	19930715	(199333)		14p
HU 64601	T	19940128	(199409)		
PT 100988	A	19940228	(199412)		
AU 649078	B	19940512	(199425)		
NZ 240247	A	19940325	(199426)		
AU 9470242	A	19950105	(199508)		
AU 658926	B	19950504	(199526)		
NZ 244114	A	19950627	(199530)		
IT 1250064	B	19950330	(199537)		
ES 2081742	A1	19960301	(199616)		
AT 9109007	A	19960615	(199629)		
ES 2081742	B1	19961001	(199645)		
TW 283710	A	19960821	(199702)		
US 5644036	A	19970701	(199732)		15p
JP 2638680	B2	19970806	(199736)		16p
EP 504363	B1	19980121	(199808)	EN	23p
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
AU 9745218	A	19980212	(199814)		
DE 69128774	E	19980226	(199814)		
BR 1100358	A3	19980414	(199821)		
ES 2112865	T3	19980416	(199822)		
KR 9615399	B1	19961113	(199930)		
AU 716402	B	20000224	(200020)		
KR 193314	B1	19990615	(200059)		
MX 195018	B	20000120	(200115)		
IL 102726	A	20020814	(200272)		
FI 110002	B1	20021115	(200282)		
FI 110003	B1	20021115	(200282)		
CA 2069481	C	20030729	(200356)	EN	

ADT WO 9207084 A1 WO 1991-GB1816 19911017; FR 2668164 A1 FR 1991-12738 19911016; AU 9187294 A AU 1991-87294 19911017, WO 1991-GB1816 19911017; FI 9202380 A WO 1991-GB1816 19911017, FI 1992-2380 19920525; GB 2253397 A WO 1991-GB1816 19911017, GB 1992-9529 19920501; EP 504363 A1 EP 1991-917891 19911017, WO 1991-GB1816 19911017; FI 9202824 A WO 1991-GB1816 19911017, Div ex FI 1992-2380 19911017, FI 1992-2824 19920617; BE 1004226 A5 BE

1991-946 19911016; FR 2677997 A1 FR 1992-9998 19920813; AU 9225321 A AU 1992-25321 19920923, Div ex AU 1991-87294 ; CH 681305 A5 WO 1991-GB1816 19911017, CH 1992-1901 19911017; CH 681455 A5 Div ex CH 1992-1901 19911017, CH 1992-2655 19911017; LU 88122 A WO 1991-GB1816 19911017, LU 1992-88122 19920527; PT 99248 A PT 1991-99248 19911016; ZA 9108259 A ZA 1991-8259 19911016; ZA 9206191 A ZA 1992-6191 19920817; JP 05504579 W JP 1991-516509 19911017, WO 1991-GB1816 19911017; HU 64601 T WO 1991-GB1816 19911017, HU 1992-2000 19911017; PT 100988 A PT 1992-100988 19921020; AU 649078 B AU 1991-87294 19911017; NZ 240247 A NZ 1991-240247 19911016; AU 9470242 A Div ex AU 1991-87294 19911017, AU 1994-70242 19940811; AU 658926 B Add to AU 1991-87294 19911017, AU 1992-25321 19920923; NZ 244114 A NZ 1991-244114 19911016; IT 1250064 B IT 1991-RM788 19911016; ES 2081742 A1 ES 1992-50029 19911017; AT 9109007 A AT 1991-9007 19911017, WO 1991-GB1816 19911017; ES 2081742 B1 ES 1992-50029 19911017; TW 283710 A TW 1991-108178 19911016; US 5644036 A Cont of US 1991-777731 19911016, Cont of US 1992-975967 19921113, Cont of US 1992-985272 19921203, Cont of US 1994-304440 19940912, US 1994-319598 19941007; JP 2638680 B2 JP 1991-516509 19911017, WO 1991-GB1816 19911017; EP 504363 B1 EP 1991-917891 19911017, WO 1991-GB1816 19911017; AU 9745218 A Div ex AU 1991-87294 19911017, AU 1997-45218 19971113; DE 69128774 E DE 1991-628774 19911017, EP 1991-917891 19911017, WO 1991-GB1816 19911017; BR 1100358 A3 BR 1997-1100358 19970428; ES 2112865 T3 EP 1991-917891 19911017; KR 9615399 B1 WO 1991-GB1816 19911017, KR 1992-701427 19920616; AU 716402 B Div ex AU 1991-87294 19911017, AU 1997-45218 19971113; KR 193314 B1 WO 1991-GB1816 19911017, Div ex KR 1992-701427 19920616, KR 1992-702699 19921030; MX 195018 B MX 1992-3794 19920629; IL 102726 A Div ex IL 1991-99761 19911016, IL 1991-102726 19911016; FI 110002 B1 WO 1991-GB1816 19911017, Div ex FI 1992-2380 19920525, FI 1992-2824 19920617; FI 110003 B1 WO 1991-GB1816 19911017, FI 1992-2380 19920525; CA 2069481 C CA 1991-2069481 19911017, WO 1991-GB1816 19911017

FDT AU 9187294 A Based on WO 9207084; GB 2253397 A Based on WO 9207084; EP 504363 A1 Based on WO 9207084; CH 681305 A5 Based on WO 9207084; LU 88122 A Based on WO 9207084; JP 05504579 W Based on WO 9207084; HU 64601 T Based on WO 9207084; AU 649078 B Previous Publ. AU 9187294, Based on WO 9207084; AU 658926 B Previous Publ. AU 9225321; NZ 244114 A Div ex NZ 240247; JP 2638680 B2 Previous Publ. JP 05504579, Based on WO 9207084; EP 504363 B1 Based on WO 9207084; DE 69128774 E Based on EP 504363, Based on WO 9207084; ES 2112865 T3 Based on EP 504363; AU 716402 B Div ex AU 649078, Previous Publ. AU 9745218; IL 102726 A Div ex IL 99761; FI 110002 B1 Previous Publ. FI 9202824; FI 110003 B1 Previous Publ. FI 9202380; CA 2069481 C Based on WO 9207084

PRAI GB 1990-22547 19901017

AB WO 9207084 A UPAB: 19931006

Following are described. (A) purified preparation of an anti-**CDw52** antibody which exhibits on size exclusion chromatography a single peak under non-reducing conditions and 2 major peaks under reducing conditions; especially the preparation exhibits on conventional SDS polyacrylamide gel electrophoresis, one main band using a non-reduced sample and two main bands using a reduced sample; (B) purified preparation of an anti-**CDw52** antibody having a specific activity greater than 0.8 KU/mg; (C) purified preparation of an anti-**CDw52** antibody, free from host cell contaminants and/or aggregates; (D) purifying an anti-**CDw52** antibody comprising (a) applying an aqs. solution of the antibody to a Protein A column so as to absorb the antibody and eluting the antibody with an acid solution, (b) applying the acidic eluate to an ion-exchange column of charged particles to absorb the antibody and then eluting the antibody with an aqs. solution of counter-charged ions and (c) applying the aqs. eluate to a size exclusion column of porous particles to retain non-antibody mols. in the porous particles and to obtain the desired antibody in selected fractions produced from the column.

Pref. the Protein A column is Protein A Sepharose and the antibody is eluted with citric acid.

USE - Purified anti-**CDw52** antibodies are useful as immunosuppressives for treating T-cell mediated disorders including severe

vasculitis, rheumatoid arthritis, systemic lupus, and also autoimmune disorders such as **multiple sclerosis**, graft vs. host disease, psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, myasthenia gravis, transplant rejection and asthma. Antibodies are also useful in treating cancers e.g. Non-Hodgkins lymphoma and leukemias. (0/0)
0/0

=>